期刊论文详细信息
Drugs in Context
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
关键词: AT04A vaccine;    low density lipoprotein cholesterol;    LDL-C;    low density lipoprotein receptors;    LDLR;    proprotein convertase subtilisin/kexin type 9;    PCSK9;    small interfering RNA;    siRNA;   
DOI  :  10.7573/dic.212511
来源: DOAJ
【 摘 要 】

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is mainly expressed in the liver but can also be found in the intestine and kidneys. PCSK9 promotes the degradation of low density lipoprotein receptors (LDLR) by reducing their recycling and targeting the receptors for lysosomal destruction, thereby decreasing the rate of removal of LDL-cholesterol from the circulation. Thus, interventions targeting PCSK9 by reducing its expression may lead to significant reductions of LDL-cholesterol and possibly decrease cardiovascular risk. The present review aims to present and discuss the current clinical and scientific data pertaining to lipid-lowering interventions targeting PCSK9.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次